PCSK9 and coronary artery disorder: Beyond the LDL-C target achievement, PCSK9 inhibitors (as an add-on therapy to statins, with or without ezetimibe) have demonstrated significant benefits in CV risk attenuation in diabetic patients with established CVD (including CAD), according to the findings of the two large landmark studies (FOURIER and ODYSSEY OUTCOMES) [66,67].